Form 4: AC Immune SA: Director Receives Equity Awards

AC Immune SA reports that Director Martin Zuegel was granted restricted stock units and stock options on June 11, 2026.

Summary

• Martin Zuegel, a Director and Interim CEO of AC Immune SA, received a grant of 33,136 restricted stock units (RSUs) on June 11, 2026, under the company's 2016 Stock Option and Incentive Plan (SOIP).
• Additionally, Zuegel was granted options to purchase 77,778 common shares under the same plan on June 11, 2026.
• These options have an exercise price of $2.62 and are set to fully vest on June 10, 2027.
• Following these transactions, Zuegel beneficially owns 71,408 common shares, which are comprised of outstanding RSUs.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it represents standard insider equity compensation rather than a significant strategic development or financial performance indicator.

Positives

• Director and Interim CEO Martin Zuegel received equity awards, indicating continued alignment of management and board interests with shareholders.
• The grant of RSUs and stock options suggests confidence in the company's future prospects by a key insider.
• The stock options have a clear vesting schedule, incentivizing long-term commitment.

Negatives

• The filing does not contain any negative financial or operational information.

Risks

• The value of the granted equity is subject to the future performance of AC Immune SA's stock price.
• Potential for dilution if a large number of options are exercised.

Future Outlook

The grant of stock options with a future vesting date implies a positive outlook for the company's stock performance, as the value of these options is tied to future share prices.

Industry Context

StockSavvy.ai notes that the issuance of equity awards to directors and officers is a common practice in the biotechnology and pharmaceutical sectors to attract, retain, and incentivize key personnel, aligning their interests with long-term shareholder value.

Stakeholder Impact

• Shareholders: The equity awards align management's interests with shareholders, potentially driving performance, but also represent potential future dilution.
• Employees: The existence of the SOIP indicates a broader equity incentive program for employees, fostering a performance-driven culture.
• Management: Directly benefits from the equity awards, contingent on company performance.

Next Steps

• Vesting of stock options on June 10, 2027.
• Expiration of stock options on June 10, 2036.

Key Dates

Keywords

AC Immune SA, ACIU, Form 4, Insider Transaction, Equity Award, Restricted Stock Units, Stock Options, Director, Interim CEO, Securities Exchange Act